Search Result

Pathways Recommended:	Anti-infection

Results for "

SARSCoV-2 infection

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SARS-CoV (107) AAK1 (2) Akt (2) Angiotensin-converting Enzyme (ACE) (8) Antibiotic (11) Apoptosis (4) Autophagy (20) Bacterial (3) Casein Kinase (1) CaSR (1) Cathepsin (2) CDK (2) Dihydroorotate Dehydrogenase (1) DNA/RNA Synthesis (5) Drug Metabolite (4) EGFR (1) Endogenous Metabolite (5) Enterovirus (1) ERK (1) FXR (4) G protein-coupled Bile Acid Receptor 1 (2) Glycosidase (1) Glycosyltransferase (1) HBV (1) HCV (2) HDAC (1) Histamine Receptor (1) Histone Methyltransferase (1) HIV (14) Influenza Virus (3) Interleukin Related (1) Isotope-Labeled Compounds (10) MDM-2/p53 (1) Microtubule/Tubulin (1) MMP (1) PAI-1 (1) Parasite (17) PKC (1) PROTACs (1) Proton Pump (1) Reference Standards (8) Ser/Thr Protease (6) Sirtuin (1) TNF Receptor (1) Toll-like Receptor (TLR) (19) VEGFR (2) Virus Protease (16)
By Research Areas:	Cancer (26) Cardiovascular Disease (2) Endocrinology (1) Infection (104) Inflammation/Immunology (12) Metabolic Disease (14)

By Targets:

SARS-CoV (107)

AAK1 (2)

Akt (2)

Angiotensin-converting Enzyme (ACE) (8)

Antibiotic (11)

Apoptosis (4)

Autophagy (20)

Bacterial (3)

Casein Kinase (1)

CaSR (1)

Cathepsin (2)

CDK (2)

Dihydroorotate Dehydrogenase (1)

DNA/RNA Synthesis (5)

Drug Metabolite (4)

EGFR (1)

Endogenous Metabolite (5)

Enterovirus (1)

ERK (1)

FXR (4)

G protein-coupled Bile Acid Receptor 1 (2)

Glycosidase (1)

Glycosyltransferase (1)

HBV (1)

HCV (2)

HDAC (1)

Histamine Receptor (1)

Histone Methyltransferase (1)

HIV (14)

Influenza Virus (3)

Interleukin Related (1)

Isotope-Labeled Compounds (10)

MDM-2/p53 (1)

Microtubule/Tubulin (1)

MMP (1)

PAI-1 (1)

Parasite (17)

PKC (1)

PROTACs (1)

Proton Pump (1)

Reference Standards (8)

Ser/Thr Protease (6)

Sirtuin (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (19)

VEGFR (2)

Virus Protease (16)

By Research Areas:

Cancer (26)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (104)

Inflammation/Immunology (12)

Metabolic Disease (14)

118

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: SARS-CoV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-175712

SARS-CoV-2 Mpro-IN-47	SARS-CoV Virus Protease	Infection
SARS-CoV-2 Mpro-IN-47 is an orally active SARS-CoV-2 Mpro reversible covalent Inhibitor. SARS-CoV-2 Mpro-IN-47 shows potent antiviral activity against several clinical variants of SARS-CoV-2. SARS-CoV-2 Mpro-IN-47 can be used for the research of infection, such as SARS-CoV-2 .

HY-178435

SARS-CoV-2 Mpro-IN-48	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-48 is a potent *SARS-CoV-2* main protease inhibitor with an IC₅₀ of 21.1 nM. SARS-CoV-2 Mpro-IN-48 exhibits potent antiviral activity against the SARS-CoV-2 JN.1 variant. SARS-CoV-2 Mpro-IN-48 can be used for the research of infection, such as COVID-19 .

HY-176232

BBH-4	SARS-CoV	Infection
BBH-4 is a *SARS-CoV-2* major protease (MPro) inhibitor. BBH-4 can be used in SARS-CoV-2 infection research .

HY-173575

SARS-CoV-2 3CLpro-IN-31	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-31 (Compound 13c) is a potent SARS-CoV-2 3CL protease (3CLpro) inhibitor of with an IC₅₀ value of 37.33 nM. SARS-CoV-2 3CLpro-IN-31 blocks viral polyprotein cleavage and inhibits SARS-CoV-2 replication. SARS-CoV-2 3CLpro-IN-31 is promising for research of SARS-CoV-2 infection .

HY-163713

SARS-CoV-2-IN-89	SARS-CoV	Infection
SARS-CoV-2-IN-89 (Compound 2) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-89 enhances IFN-I responses to SARS-CoV-2 infection in A549.hACE2 cells .

HY-149304

SARS-CoV-2-IN-40	SARS-CoV	Infection
SARS-CoV-2-IN-40 (Compound 19) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC₅₀s of 100 nM and 160 nM respectively .

HY-175461

AVI-4206	SARS-CoV	Infection
AVI-4206 is a selective Mac1 inhibitor with an lC₅₀ of 64 nM. AVI-4206 reduces viral replication, restores an interferon response, and leads to a survival benefit in an animal model of *SARS-CoV-2* infection. AVI-4206 can be used the study of *SARS-CoV-2* infection .

HY-162604

SARS-CoV-2-IN-90	SARS-CoV	Infection
SARS-CoV-2-IN-90 (compound 3i) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-90 can be used in coronavirus infection related research .

HY-157305

Jun11165	SARS-CoV	Infection
Jun11165 is a SARS-CoV-2 PL ^pro inhibitor (IC₅₀ ≤ 0.6 μM), which inhibits SARS-CoV-2 with an EC₅₀ value of ≤ 6 μM. Jun11165 can be used in the research of viral infections .

HY-174373

SARS-CoV-2-IN-113	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
SARS-CoV-2-IN-113 (Compound 24) is a sulfonohydrazide derivative against *SARS-CoV-2* infection with an IC₅₀ of 8.320 μM. SARS-CoV-2-IN-113 exerts potent antiviral effects by inhibiting the entry and replication of *SARS-CoV-2, and downregulating the expression of genes and proteins such as Spike, ACE-2, and RdRp. SARS-CoV-2-IN-113* has high selectivity and low cytotoxicity, and can be used in the research of SARS-CoV-2 .

HY-146381

SARS-CoV-2-IN-20	SARS-CoV	Infection
SARS-CoV-2-IN-20 (Compound 1a) is a potent inhibitor of *SARS-CoV-2* with an EC₅₀ of 6.5 μM. SARS-CoV-2-IN-20 has the potential for the research of infection diseases .

HY-178772

SARS-CoV-2 Mpro-IN-50	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-50 (Compound 30) is a noncovalent SARS-CoV-2 Mpro inhibitor with an IC₅₀ of 14  nM. SARS-CoV-2 Mpro-IN-50 is also a pan-CoV Mpro inhibitor with IC₅₀s of 20-190 nM for SARS-CoV-1 Mpro, 229E Mpro, HKU1 Mpro, MERS Mpro, NL63 Mpro and OC43 Mpro. SARS-CoV-2 Mpro-IN-50 has significant antiviral activity against the SARS-CoV-2 omicron variant (EC₅₀: 22  nM). SARS-CoV-2 Mpro-IN-50 can be used for coronavirus infections research .

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-144833

SARS-CoV-2 3CLpro-IN-1	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL ^pro. 3CL ^pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .

HY-146379

SARS-CoV-2-IN-19	SARS-CoV	Infection
SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of *SARS-CoV-2* with an EC₅₀ of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks. SARS-CoV-2-IN-19 has the potential for the research of infection diseases .

HY-174251

(±)-Tuaimenal A	SARS-CoV Virus Protease	Infection
(±)-Tuaimenal A ((+)-1) is a secondary metabolite and a derivative of Sesamol (HY-N1417). (±)-Tuaimenal A has potent inhibitory activity against SARS-CoV-2 3CLpro with an IC₅₀ of 33.3  μM. (±)-Tuaimenal A can be used for SARS-CoV-2 infection research .

HY-178188

TPG-20A	SARS-CoV	Infection
TPG-20A is a *SARS-CoV-2* main protease inhibitor with an IC₅₀ of 27.8 nM. TPG-20A also inhibits MERS-CoV main protease. TPG-20A can be used for the research of infection, such as SARS-CoV-2 .

HY-178318

LRH-0003	SARS-CoV	Infection
LRH-0003 is an inhibitor of the Macrodomain 1 (Mac1) of nonstructural protein 3 (NSP3) from SARS-CoV-2, with an IC₅₀ value of 1.7 μM. LRH-0003 can be used for the research antiviral infection targeting SARS-CoV-2 .

HY-168916

Jun13296	SARS-CoV Virus Protease
Jun13296 is an orally active quinoline SARS-CoV-2 papain-like protease inhibitor (IC₅₀ = 0.13 µM, K_i = 8.8 nM). Jun13296 exhibits potent inhibition against SARS-CoV-2 variants and Nirmatrelvir (HY-138687)-resistant mutants. Jun13296 improves lung viral titers, and prevents lung tissue damage in a SARS-CoV-2 infection model .

HY-175029

ALG-097558	SARS-CoV Virus Protease	Infection
ALG-097558 is an orally active 3CLpro inhibitor. ALG-097558 demonstrates pan-coronavirus activity against various *SARS-CoV-2* variants as well as other human coronaviruses (HCoVs) such as *SARS-CoV-1, α-HCoV 229E, and β-HCoV OC43. ALG-097558 demonstrates potent inhibition with IC₅₀s* of 2 nM (SARS-CoV-2 3CLpro) and 6 nM (229E 3CLpro). ALG-097558 demonstrates antiviral activity in the SARS-CoV-2 hamster infection model. ALG-097558 can be used for the study of viral infections[1].

HY-174233

PROTAC SARS-CoV-2 Degrader-1	PROTACs SARS-CoV Virus Protease	Infection
PROTAC SARS-CoV-2 Degrader-1 (Compound LLP019) is a SARS-CoV-2 M ^Pro PROTAC degrader with a DC₅₀ value of 4.7 μM. PROTAC SARS-CoV-2 Degrader-1 induces M ^Pro ubiquitination and proteasomal degradation to inhibit SARS-CoV-2 replication. PROTAC SARS-CoV-2 Degrader-1 is promising for research of COVID-19 and related coronavirus infections. (Pink: DH03 (HY-32717); Black: linker (HY-42149); Blue: Thalidomide-4-O-CH2-COO(t-Bu) (HY-42771) .

HY-168441

NCGC00537446	SARS-CoV	Infection
NCGC00537446 is a dual Nsp14 MTase/ExoN inhibitor. NCGC00537446 can be used for the research of SARS-CoV-2 replication and infection .

HY-163912

JZD-07	SARS-CoV	Infection
JZD-07 is a potent SARS-CoV 3CLpro inhibitor. JZD-07 can be used in the study of *SARS-CoV-2* infection .

HY-161261

SARS-CoV-2-IN-81	AAK1 SARS-CoV	Infection
SARS-CoV-2-IN-81 (compound 12e) is a potent AAK1 inhibitor with an IC₅₀ value of 9.38 nM. SARS-CoV-2-IN-81 shows anti-viral property against *SARS-CoV-2. SARS-CoV-2-IN-81* attenuates AAK1-induced phosphorylation of AP2M1 threonine 156 and disrupts the direct interaction between AP2M1 and ACE2, ultimately inhibiting SARS-CoV-2 infection .

HY-155186

SARS-CoV-2 3CLpro-IN-19	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.7 μM). SARS-CoV-2 3CLpro-IN-19 has broad-spectrum activity against Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) infection in human cells, with EC₅₀ values between 30-69 nM .

HY-169092

PF-07957472	SARS-CoV Virus Protease	Infection
PF-07957472 (Compound 4) is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor. PF-07957472 shows cytopathic effect in SARS-CoV-2 infected NHBE cells (EC₅₀ = 13.9 nM). PF-07957472 shows antiviral effect in a mouse-adapted model of COVID-19 infection model .

HY-153228

Pomotrelvir 1 Publications Verification PBI-0451	SARS-CoV	Infection
Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (M ^pro), with an IC₅₀ of 24 nM for wild-type SARS-CoV-2 M ^pro. Pomotrelvir inhibits viral polyprotein processing, thereby preventing viral replication. Pomotrelvir has shown broad antiviral activity against multiple SARS-CoV-2 variants (including Omicron) in cell-based experiments, and has an additive effect when combined with nucleoside analogs that target viral RNA synthesis. Pomotrelvir is primarily used for the research and development of COVID-19 antiviral drugs, especially for infections caused by SARS-CoV-2 and its variants .

HY-175344

TMP1	SARS-CoV Virus Protease Ser/Thr Protease	Infection Inflammation/Immunology
TMP1 is an orally active bispecific inhibitor of M pro (IC₅₀ = 312.5 nM)/TMPRSS2 (IC₅₀ = 1.28 μM, K_D = 10.10 μM). TMP1 exhibits broad protection against different *SARS-CoV-2* variants in vitro. TMP1 cross-protects against highly pathogenic coronaviruses (SARS-CoV-1, *SARS-CoV-2, and MERS-CoV) in vivo and effectively blocks the transmission of SARS-CoV-2. TMP1 can inhibit infection* by *SARS-CoV-2* escape mutants that are resistant to Nivolumab (HY-P9903). TMP1 can be used in coronavirus research .

HY-P10855

S1b3inL1	SARS-CoV	Infection
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity .

HY-170767

SARS-CoV-2-IN-109	SARS-CoV	Infection
SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting *SARS-CoV* with in vivo anti-infection activity. SARS-CoV-2-IN-109 targets the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) (EC₅₀=26.5 μM), blocking the entry of SARS-CoV-2 into VeroE6 cells (EC₅₀=17.0 μM). The CC50 of SARS-CoV-2-IN-109 for VeroE6 cells is >100 μM .

HY-172214

AB-343	SARS-CoV Virus Protease	Infection
AB-343 is a selective covalent inhibitor of SARS-CoV-2 M ^pro, with an IC₅₀ of 8 nM and a K_i of 2.8 nM. AB-343 can effectively inhibit the main proteases of *SARS-CoV-2* and many other coronaviruses, and is also active against some resistant variants. AB-343 can be used in the research of treating coronavirus infection-related diseases .

HY-161844

Virapinib	SARS-CoV	Infection
Virapinib is a macropinocytosis inhibitor with antiviral activities. Virapinib inhibits macropinocytosis, limiting this entry route for the viruses. Virapinib inhibits infection by *SARS-CoV-2, as well as by additional viruses, such as mpox virus* and TBEV .

HY-19727A

FOY 251 2 Publications Verification	Ser/Thr Protease SARS-CoV	Metabolic Disease
FOY 251, an anti-proteolytic active metabolite Camostate (HY-13512), acts as a proteinase inhibitor . FOY 251 inhibits SARS-CoV-2 infection in cells assay .

HY-174439

Nsp12-IN-2	SARS-CoV Virus Protease Drug Metabolite	Infection
Nsp12-IN-2 (Compound 8), the triphosphate metabolite of 4'-thiouridine (HY-W113081), is a SARS-CoV-2 Nsp12 inhibitor. Nsp12-IN-2 inhibits the RNA-dependent RNA polymerase (RdRp) activity of the SARS-CoV-2 Nsp12-Nsp7-Nsp8 complex, terminates RNA synthesis and also blocks the RNAylation and NMPylation of Nsp9. Nsp12-IN-2 is promising for research of infections caused by SARS-CoV-2, other coronaviruses, and other RNA viruses .

HY-P99604

Cilgavimab AZD-1061; COV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of *SARS-CoV-2* infection .

HY-173148

TKB272	SARS-CoV	Infection
TKB272 is an orally active and selective antiviral agent targeting the main protease (Mpro) of *SARS-CoV-2. It effectively blocks the infection* and replication of various SARS-CoV-2 strains, including Omicron variants such as XBB.1.5 and EG.5.1. The enzymatic inhibitory activity of TKB272 shows an IC₅₀ of 0.7 µM (against SARS-CoV-2WK-521 Mpro), and its antiviral activity at the cellular level reaches an EC₅₀ as low as 2.6 nM (against BQ.1.1 strain in HeLahACE2-TMPRSS2 cells), with a cytotoxicity CC₅₀ of 98 µM, indicating no apparent toxicity. In addition, TKB272 significantly suppresses the replication of SARS-CoV-2XBB.1.5 in B6.Cg-Tg(K18-hACE2)2-Prlmn/J transgenic mouse models. TKB272 holds promise for research in the field of SARS-CoV-2 infection .

HY-19727

FOY 251 free base	Ser/Thr Protease SARS-CoV	Infection Metabolic Disease
FOY 251 free base, an anti-proteolytic active metabolite of Camostate (HY-13512), acts as a proteinase inhibitor . FOY 25 free base inhibits SARS-CoV-2 infection in cells assay .

HY-178156

DHODH-IN-31	Dihydroorotate Dehydrogenase SARS-CoV	Infection
DHODH-IN-31 is a human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ of 0.59 μM. DHODH-IN-31 exhibits antiviral activity. DHODH-IN-31 can be used for the research of infection, such as SARS-CoV-2 .

HY-136597

Remdesivir O-desphosphate acetonide impurity 3 Publications Verification	DNA/RNA Synthesis SARS-CoV	Infection
Remdesivir O-desphosphate acetonide impurity is an impurity of Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity and is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro .

HY-P990816

Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) reacts with the N-terminal domain (NTD) in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) can be used for the detections of flow cytometry and ELISA in SARS-CoV-2 infection .

HY-144798

FWM-5	SARS-CoV	Infection
FWM-5 is a potent NSP13 helicase inhibitor. SARS-COV-2 NSP13 helicase enzyme plays crucial role in the virus life cycle. FWM-5 has the potential for the research of infection diseases .

HY-171160

WYFA-15	SARS-CoV	Infection
WYFA-15 is a sphingomyelin synthase 1 (SMS1) inhibitor that protects mice against lethal SFTSV infection and reduce *SARS-CoV-2* replication and pathogenesis. WYFA-15 can be utilized in anti-virus research .

HY-170504

ZHAWOC25153	SARS-CoV Virus Protease	Infection
ZHAWOC25153 (Compound 17o) is a SARS-CoV-2 papain-like cysteine protease (PLpro) inhibitor, with an IC₅₀ of 7 μM. ZHAWOC25153 exhibits antiviral activity and can be used in research within the field of anti-infection .

HY-N3389

Licoisoflavone A 1 Publications Verification	SARS-CoV Sirtuin CDK Apoptosis	Infection Metabolic Disease Cancer
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on *SARS-CoV-2* infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and *SARS-CoV-2* infection .

HY-P990814

Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) reacts with the receptor binding domain (RBD) epitope B in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can be used for the research of SARS-CoV-2 infection .

HY-P990815

Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection .

HY-149050

Viral polymerase-IN-1 hydrochloride	Influenza Virus SARS-CoV	Infection
Viral polymerase-IN-1 hydrochloride, a Gemcitabine (HY-17026) derivative, potently inhibits influenza A and B viruses infection with IC₉₀ values of 11.4-15.9 μM. Viral polymerase-IN-1 hydrochloride is active against *SARS-CoV-2* infection. Viral polymerase-IN-1 hydrochloride suppresses influenza virus infection by affecting viral RNA replication/transcription in cells .

HY-B1370A

(S)-Hydroxychloroquine (S)-HCQ	Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy	Infection
(S)-Hydroxychloroquine ((S)-HCQ) is the enantiomer of Hydroxychloroquine . Hydroxychloroquine, a synthetic antimalarial agent, inhibits Toll-like receptor 7/9 (TLR7/9) signaling, and shows efficiently inhibits SARS-CoV-2 infection in vitro .

HY-P11032

Mp-4D7-pF2	SARS-CoV Virus Protease	Infection
Mp-4D7-pF2, a cell-penetrating bicyclic peptide, is a noncovalent SARS-CoV-2 main protease inhibitor with an IC₅₀ of 4.51 μM. Mp-4D7-pF2 has an antiviral activity against SARS-CoV-2 with no cytotoxicity. Mp-4D7-pF2 can used for COVID-19 infections research .

HY-B1370B

(R)-Hydroxychloroquine (R)-HCQ	Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy	Infection
(R)-Hydroxychloroquine is the enantiomer of Hydroxychloroquine . Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

Cat. No.	Product Name	Target	Research Area

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-P10855

S1b3inL1	SARS-CoV	Infection
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity .

HY-P11032

Mp-4D7-pF2	SARS-CoV Virus Protease	Infection
Mp-4D7-pF2, a cell-penetrating bicyclic peptide, is a noncovalent SARS-CoV-2 main protease inhibitor with an IC₅₀ of 4.51 μM. Mp-4D7-pF2 has an antiviral activity against SARS-CoV-2 with no cytotoxicity. Mp-4D7-pF2 can used for COVID-19 infections research .

HY-P10975

P9R	SARS-CoV Influenza Virus Enterovirus	Infection
P9R is an antiviral peptide. P9R has broad-spectrum antiviral activities against the coronaviruses (SARS-CoV-2, MERS-CoV and *SARS-CoV), A(H1N1)pdm09, A(H7N9) virus, and rhinovirus. P9R directly binds to viruses and inhibits virus-host endosomal acidification. P9R significantly protects mice from A(H1N1)pdm09 infection* without generating drug-resistant virus. P9R can be used for pH-dependent respiratory viruses research .

Cat. No.	Product Name	Target	Research Area

HY-P99604

Cilgavimab AZD-1061; COV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of *SARS-CoV-2* infection .

HY-P990816

Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) reacts with the N-terminal domain (NTD) in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) can be used for the detections of flow cytometry and ELISA in SARS-CoV-2 infection .

HY-P990814

Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) reacts with the receptor binding domain (RBD) epitope B in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can be used for the research of SARS-CoV-2 infection .

HY-P990815

Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection .

HY-P991491

VIR-7229	SARS-CoV Influenza Virus	Infection
VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3389

Licoisoflavone A 1 Publications Verification	Flavonoids Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Metabolic Disease Plants Glycyrrhiza uralensis Fisch. Disease Research Fields Isoflavones	SARS-CoV Sirtuin CDK Apoptosis
Licoisoflavone A is an orally active isoflavone. Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. Licoisoflavone A inhibits the CDK2-Cyclin E1 axis. Licoisoflavone A inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. Licoisoflavone A shows a dose-dependent inhibition effect on *SARS-CoV-2* infection. Licoisoflavone A exhibits significant anti-tumor efficacy in mice bearing CT26 cell subcutaneous xenografts. Licoisoflavone A can be used for the study of colorectal cancer and *SARS-CoV-2* infection .

HY-N10109A

Gallinamide A TFA	Natural Products Microorganisms Source classification	SARS-CoV Parasite Cathepsin
Gallinamide A TFA is a linearly depositing peptide and a potent inhibitor of cathepsin L (CatL) (IC₅₀: 17.6 pM). Gallinamide A TFA inhibits SARS-CoV-2 infection by inhibiting CatL (EC₅₀: 28 nM). Gallinamide A TFA also inhibits Plasmodium falciparum (IC₅₀: 50 nM) .

HY-134222A

N-Acetylserine N-Acetyl-L-serine	Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
N-Acetylserine (N-Acetyl-L-serine) is a physiological inducer of cysteine biosynthesis and activator of CysB. N-Acetylserine can bind to the CysB apoprotein. N-Acetylserine stimulates cysJIH transcription in vitro. N-Acetylserine can be used in the research of SARS-CoV-2 infection .

HY-A0097

Teicoplanin 1 Publications Verification Antibiotic MDL-507; MDL-507	Infection Microorganisms Source classification Polyphenols Disease Research Fields	Bacterial Antibiotic
Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-126419

Kobophenol A	Infection Classification of Application Fields Source classification Cyperaceae Phenols Polyphenols Plants Disease Research Fields Carex kobomugi Ohwi	SARS-CoV PKC
Kobophenol A, an oligomeric stilbene, blocks the interaction between the ACE2 receptor and S1-RBD with an IC₅₀ of 1.81 μM and inhibits *SARS-CoV-2* viral infection in cells with an EC₅₀ of 71.6 μM. Kobophenol A inhibits the activity of partially purified rat brain protein kinase C (PKC) with an IC₅₀ of 52 µM .

HY-110066

(Z)-Guggulsterone 5+ Cited Publications	Classification of Application Fields Commiphora myrrha (Nees) Engl. Source classification Plants Burseraceae Disease Research Fields Steroids Cancer	Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and *SARS-CoV-2* infection .

HY-A0097A

Teicoplanin sodium Antibiotic MDL-507 sodium; MDL-507 sodium	Source classification Phenols Polyphenols Endogenous metabolite	Antibiotic HIV SARS-CoV
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .

HY-134222AR

N-Acetylserine (Standard)	Natural Products Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite
N-Acetylserine (Standard) is the analytical standard of N-Acetylserine (HY-134222A). This product is intended for research and analytical applications. N-Acetylserine (N-Acetyl-L-serine) is a physiological inducer of cysteine biosynthesis and activator of CysB. N-Acetylserine can bind to the CysB apoprotein. N-Acetylserine stimulates cysJIH transcription in vitro. N-Acetylserine can be used in the research of SARS-CoV-2 infection .

HY-N14351

Ferrocin A	Natural Products Microorganisms Source classification	SARS-CoV Bacterial Antibiotic
Ferrocin A is a lipopeptide compound that targets the *SARS-CoV-2* RNA-dependent RNA polymerase (nsp12). Ferrocin A can stably bind to nsp12, and as an iron-chelating peptide, it reduces the concentration of free iron in the environment via complexation, thereby inhibiting bacterial growth by repressing the acquisition of essential metal cations. As an iron-chelating antiviral molecule, Ferrocin A may be used in studies related to COVID-19 and bacterial infections .

HY-110066R

(Z)-Guggulsterone (Standard)	Commiphora myrrha (Nees) Engl. Source classification Plants Burseraceae Steroids	Reference Standards Apoptosis VEGFR Akt Angiotensin-converting Enzyme (ACE) SARS-CoV FXR
(Z)-Guggulsterone (Standard) is the analytical standard of (Z)-Guggulsterone. This product is intended for research and analytical applications. (Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis . (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection .

HY-B1513

α-Cyclodextrin 2 Publications Verification	Zea mays L. Polysaccharides Classification of Application Fields Gramineae Source classification Other Diseases Plants Disease Research Fields Saccharides	Microtubule/Tubulin SARS-CoV
α-Cyclodextrin (α-CD) is a soluble fiber derived from corn. α-Cyclodextrin can deplete sphingolipids and phospholipids from cell membranes. α-Cyclodextrin interacts with tubulin. α-Cyclodextrin improves defenses against *SARS-CoV-2* infection. α-Cyclodextrin enhances the anticancer efficacy of Crcumin (HY-N0005) against breast, lung and cervical cancer. α-Cyclodextrin has beneficial effects on body weight and blood lipids .

HY-13771

Ursodeoxycholic acid Maximum Cited Publications 20 Publications Verification Ursodeoxycholate; Ursodiol; UDCA	Human Gut Microbiota Metabolites Other disease Classification of Application Fields Source classification Disease markers Endogenous metabolite Disease Research Fields Steroids Cancer	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing *SARS-CoV-2* infection. Orally active .

HY-13771R

Ursodeoxycholic acid (Standard) Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)	Human Gut Microbiota Metabolites Microorganisms Other disease Source classification Disease markers Endogenous metabolite Steroids	Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

Cat. No.	Product Name	Chemical Structure

HY-W031727S

Hydroxychloroquine-d4-1 sulfate
Hydroxychloroquine-d₄-1 (sulfate) is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-B0372AS

Bromhexine-d3 hydrochloride

Bromhexine-d₃ (hydrochloride) is deuterium labeled Bromhexine (hydrochloride). Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC₅₀ of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions .

HY-17589AS

Chloroquine-d5 1 Publications Verification
Chloroquine-d₅ is deuterium labeled Chloroquine (HY-17589A). Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-W031727S1

Hydroxychloroquine-d5
Hydroxychloroquine-d₅ is the deuterium labeled Hydroxychloroquine . Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-W707562

FOY 251-d4
FOY 251-d₄ is the deuterium labeled FOY 251 (HY-19727A). FOY 251, an anti-proteolytic active metabolite Camostate (HY-13512), acts as a proteinase inhibitor . FOY 251 inhibits SARS-CoV-2 infection in cells assay .

HY-B1370S

Hydroxychloroquine-d4 sulfate
Hydroxychloroquine-d₄ (sulfate) is the deuterium labeled Hydroxychloroquine sulfate. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-17589S

Chloroquine-d5 diphosphate

Chloroquine-d₅ (diphosphate) is the deuterium labeled Chloroquine (phosphate). Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-17589S1

Chloroquine-d4 phosphate

Chloroquine-d₄ (phosphate) is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM) .

HY-134222AS

N-Acetylserine-d3
N-Acetylserine-d₃ is the deuterium labeled N-Acetylserine (HY-134222A). N-Acetylserine (N-Acetyl-L-serine) is a physiological inducer of cysteine biosynthesis and activator of CysB. N-Acetylserine can bind to the CysB apoprotein. N-Acetylserine stimulates cysJIH transcription in vitro. N-Acetylserine can be used in the research of SARS-CoV-2 infection .

HY-W777545

4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d4
4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d₄ is the deuterium labeled Hydroxychloroquine Impurity E (HY-131262). Hydroxychloroquine Impurity E is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro .

HY-113478S

Ursodeoxycholic acid-d4

Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .

Cat. No.	Product Name		Classification